Your browser doesn't support javascript.
loading
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.
Hernando-Calvo, Alberto; Vila-Casadesús, Maria; Bareche, Yacine; Gonzalez-Medina, Alberto; Abbas-Aghababazadeh, Farnoosh; Lo Giacco, Deborah; Martin, Agatha; Saavedra, Omar; Brana, Irene; Vieito, Maria; Fasani, Roberta; Stagg, John; Mancuso, Francesco; Haibe-Kains, Benjamin; Han, Ming; Berche, Roger; Pugh, Trevor J; Mirallas, Oriol; Jimenez, Jose; Gonzalez, Nadia Saoudi; Valverde, Claudia; Muñoz-Couselo, Eva; Suarez, Cristina; Diez, Marc; Élez, Elena; Capdevila, Jaume; Oaknin, Ana; Saura, Cristina; Macarulla, Teresa; Galceran, Joan Carles; Felip, Enriqueta; Dienstmann, Rodrigo; Bedard, Philippe L; Nuciforo, Paolo; Seoane, Joan; Tabernero, Josep; Garralda, Elena; Vivancos, Ana.
Afiliação
  • Hernando-Calvo A; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G2C4, Can
  • Vila-Casadesús M; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Bareche Y; Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X0A9, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, QC H3T1J4, Canada.
  • Gonzalez-Medina A; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Abbas-Aghababazadeh F; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada.
  • Lo Giacco D; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Martin A; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Saavedra O; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Brana I; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Vieito M; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Fasani R; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Stagg J; Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X0A9, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, QC H3T1J4, Canada.
  • Mancuso F; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Haibe-Kains B; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada; Department of Computer Science, University of Toronto, Toronto, ON M5S2E4, Canada; Ontario Institute for Cancer Research, Toron
  • Han M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada.
  • Berche R; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Pugh TJ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada; Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada.
  • Mirallas O; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Jimenez J; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Gonzalez NS; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Valverde C; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Muñoz-Couselo E; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Suarez C; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Diez M; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Élez E; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Capdevila J; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Oaknin A; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Saura C; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Macarulla T; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Galceran JC; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Felip E; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Dienstmann R; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Bedard PL; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G2C4, Canada.
  • Nuciforo P; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Seoane J; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Tabernero J; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Garralda E; Department of Medical Oncology, Vall D'Hebron University Hospital, 08035 Barcelona, Spain; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Vivancos A; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain. Electronic address: avivancos@vhio.net.
Med ; 4(10): 710-727.e5, 2023 10 13.
Article em En | MEDLINE | ID: mdl-37572657
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Med Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Med Ano de publicação: 2023 Tipo de documento: Article